Ginkgo Bioworks, Inc.

We're #hiring a new Mechatronics Engineer 2 in California. Apply today or share this post with your network.

Over the past year, I’ve had the privilege of working alongside Ministry of Health Rwanda, Rwanda Biomedical Centre, CEPI (Coalition for Epidemic Preparedness Innovations), IQVIA on the #100DaysMission pilot in Rwanda - a collaboration to connect disease surveillance to countermeasure development. Less than two weeks after the Marburg outbreak was declared in Rwanda, a clinical trial of the Sabin Vaccine Institute's experimental Marburg vaccine began. I am proud to contribute to the work enabling the 100 Days Mission pilot in Rwanda, and to a historic response enabled by national leadership in Rwanda and global partnership. Minister Sabin Nsanzimana’s and CEPI CEO Richard Hatchett reflect here: https://lnkd.in/esUrZxMC Our work continues informed by the lessons learned! #100DaysMission in action - Watch this space!

Modular lab automation enthusiasts! We want to show you something big at SLAS 2025. Most biotech research is done at the bench. But many problems demand automated solutions for throughput, quality, or walk-away time: protein engineering, data generation for AI, cell-based assays, strain engineering, etc.. The challenge? Existing automation systems are rigid, slow to deploy, and difficult to support. We've been developing something different at Ginkgo: truly modular, integrated lab automation with remote control and support capabilities. Our Reconfigurable Automation Carts (RACs) are battle tested solutions born from solving our own complex biological challenges. Want to see the future of lab automation? Book a live demo at SLAS or swing by booth #2651: https://lnkd.in/gMd_Vp4N What makes RACs unique? - Modular design that adapts to your workflow - Fast site installation - Modern web-based control software - Remote control and support ready - Developed by scientists, for scientists See you in San Diego!

Ginkgo Biosecurity is partnering with Virgin Atlantic's Passenger and Employee Health Teams to tailor its Horizon digital pathogen monitoring platform to the aviation industry’s specific needs. The ability to identify new outbreaks early and monitor any existing ones in real time is critical for an airline’s Health Team to inform crews and passengers about potential risks in destination countries and recommend mitigating actions. Collecting, validating, monitoring, and interpreting these data is exceptionally resource-intensive since they are often unstructured, of varying reliability, and frequently require epidemiological expertise to interpret. This effort-intensive and complex activity reduces the time and effort the Health Teams have to dedicate to essential strategic activities such as the development of mitigation plans and communication with decision-makers, crews, and passengers. Virgin Atlantic supports Ginkgo in developing a digital biosurveillance solution tailored to a global airline traveling to multiple continents. Over a six-month pilot, the team is leveraging Ginkgo’s Horizon System, which detects and monitors infectious disease events worldwide by aggregating, structuring, and validating hundreds of different open-source epidemiological data feeds leveraging AI and a dedicated team of trained epidemiologists. These include: - Early warning data feed: a pipeline that detects, monitors, and flags outbreaks of potential concern, with metrics including summary epidemiological data and a sophisticated risk score for each outbreak. - Structured epidemiological data: high-resolution, true-to-source data on the spatiotemporal evolution of 3,300+ epidemics dating back over 60 years. Learn more about this pilot, and Horizon, a Common Operational Picture for global biological risks on our website: https://hubs.la/Q0309GwD0

We're #hiring a new Manager, Environmental Health & Safety in Massachusetts. Apply today or share this post with your network.

Some more juicy AI goodness from Alyssa Morrow and Siqi Zhao on our AI team here at Ginkgo. This is a really interesting tool that complements the gene therapy discovery work that my group is working on. Do check out the whitepaper and if you want to chat CRE discovery and optimization please reach out! #groweverything

Two new models from Ginkgo AI! We're excited to see what you'll build with these. Promoter-0 for predicting RNA expression levels in synthetic constructs. https://hubs.la/Q030bvv90 Antibody Discrete Diffusion generating de novo antibody sequences. https://hubs.la/Q030btl90

California's State of Emergency proclamation is an important recognition of the need to respond definitively to the growing threat posed by H5N1. Proactive testing and sequencing just makes sense – heartland security is an issue that has consequences for all of us, and everyone should support proactive measures against threats like this. All of us across America depend on our farmers and food infrastructure every day, and they should be able to depend on us. State and national governments can provide critical support, empowering America's biosecurity industrial base to snap in safeguards that keep us all informed. Our response needs to get smarter: testing alone will mean we are catching up to the spread of the disease. Deploying genomic surveillance, the sequencing of milk samples (especially those that test positive) will allow us to detect emerging variants, develop comprehensive testing panels, and keep on pace with the biology at play here. Thankfully, the same infrastructure we built to support our COVID response can be deployed against bird flu. We stand ready, alongside our partners, including labs that test roughly half of the US milk supply, to support these biosecurity efforts.

Boston locals! The next Engineering Biology club happens Thursday, January 9th at 5:30 PM. Register here 👇 https://hubs.la/Q03039QL0 This time we're doing a very exicing crossover event with Bits in Bio! Sign up to give a lightning talk and tell us what you're working on.

Great to be back in Berlin and discuss all things biotech, security and sovereignty with a wide range of stakeholders from the German government, business, science and think tank community yesterday. My recap: What's the baseline? Germany has a good foundation in the life sciences with strong biotech and pharmaceutical companies, robust IP protections, and an excellent basic research environment, but several factors are undermining Germany's competitiveness. What needs to happen? The Lab-to-market transmission mechanism is often broken in the German biotech sector: we have a mismatch between the high quality of basic research and the ability to commercialize these technologies for the benefit of society. Founders need better access to venture and growth capital, otherwise they will build their cutting-edge companies elsewhere. Some well intended regulations and cultural factors around GMOs and administrative red tape can also a big liability. The list goes on. The problems have been known for a while. Time to act. Thanks to the Global Public Policy Institute (GPPi) for having me and organizing this important discussion!